Maropitant

DB11427ExperimentalVet approvedSmall molecule

Maropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. It was approved by... It was approved by the FDA in 2007 for use in dogs, and more recently has also been approved for use in cats.

Chemical structure of Maropitant
Mechanism
Curator reviewed
Formula / weight
C32H40N2O · 468.685 g/mol (avg)

Resolves to

Compound
UNII4XE2T9H4DHCAS147116-67-4ChEMBLCHEMBL2111099
Clinical / RWD
RxNorm715869
Structure
InChIKeyOMPCVMLFFSQFIX-CONSDPRKSA-NSMILES[H][C@]1(NCC2=CC(=CC=C2OC)C(C)(C)C)C2CCN(CC2)[C@@]1([H])C(C1=CC=CC=C1)C1=CC=CC=C1
Targets
P25103TACR1
Transporters
P08183ABCB1

What you can answer from here — as of September 21, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1TransporterSubstrate / inhibitor direction, not just membership
Listed above
15+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Maropitant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In